<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>OPERATOR-BCSC1819_S06_C24_p001-014_1P</title>
		<link href="OPERATOR-BCSC1819_S06_C24_p001-014_1P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="OPERATOR-BCSC1819_S06_C24_p001-014_1P" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter</span><span class="cn-chap"> </span>24</p>
			<p class="chapter-title ParaOverride-1">Uveitis in the Pediatric Age Group</p>
			<p class="body-text--no-indent-"><span class="italic">Uveitis</span> is broadly defined as inflammation of the uvea, including the iris, ciliary body, and choroid. See BCSC Section&#160;9, <span class="italic">Intraocular Inflammation and Uveitis,</span> for a more detailed description of the clinical features and inflammatory mechanisms of the conditions discussed in this chapter.</p>
			<p class="h1 ParaOverride-2">Epidemiology</p>
			<div id="Chapt24_Top1">
			<p class="body-text--no-indent-">The prevalence of pediatric uveitis varies among studies, with pediatric cases accounting for 2%–14% of all uveitis cases. The distribution between the sexes is similar to that of uveitis in adults, showing a slight female preponderance. The mean age at diagnosis is 8–9&#160;years, and 75% of patients have bilateral disease. In the United States, approximately 62% of pediatric patients with uveitis are white. The 2 major etiologies of uveitis in &#173;children are idiopathic (25%–54% of cases) and juvenile idiopathic arthritis (15%–47% of cases). Most types of uveitis are not inherited.</p>
			</div>
			<p class="h1 ParaOverride-2">Classification</p>
			<div id="Chapt24_Top2">
			<p class="body-text--no-indent-">As in adults, uveitis in &#173;children can be classified according to several &#173;factors, including anatomical location, pathology (granulomatous or nongranulomatous), course (acute, chronic, or recurrent), or etiology (traumatic, immunologic, infectious [exogenous or endogenous], masquerade, or idiopathic). This chapter categorizes and describes uveitic entities using the basic anatomical classification of uveitis into 4 groups: anterior, intermediate, posterior, and panuveitis. Anatomical location of the uveitis can be helpful in determining etiology (<span class="xref-table">&#173;Table&#160;24-1</span>). Results of a recent claims-&#173;based study of uveitis in the United States showed that anterior uveitis accounted for 75% of pediatric uveitis cases, with posterior uveitis and panuveitis accounting for the remaining 25%.</p>
			<p class="reference--journal--single"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Thorne%20JE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27608193"><span class="Hyperlink">Thorne JE</span></a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Suhler%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27608193"><span class="Hyperlink">Suhler E</span></a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Skup%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=27608193"><span class="Hyperlink">Skup M</span></a>, et&#160;al. Prevalence of noninfectious uveitis in the United States: a&#160;claims-&#173;based analy&#173;sis. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27608193"><span class="Hyperlink_italic">JAMA Ophthalmol.</span></a> 2016;134(11):1237–1245.</p>
			</div>
			<p class="h1 ParaOverride-2">Anterior Uveitis</p>
			<div id="Chapt24_Top3">
			<p class="body-text--no-indent-">Anterior uveitis primarily involves inflammation of the iris and ciliary body. When the anterior chamber is the primary site where inflammation is observed, the term <span class="italic">iritis</span> may be used for this inflammation.When inflammation is also observed in the anterior vitreous, the term <span class="italic">iridocyclitis</span> may be used.</p>
			<p class="h2">Juvenile Idiopathic Arthritis</p>
			<p class="body-text--no-indent-"><span class="italic">Juvenile idiopathic arthritis (JIA)</span> (formerly, <span class="italic">juvenile rheumatoid arthritis</span>) is the most common identifiable etiology of childhood anterior uveitis. JIA is defined as arthritis of at least 6 weeks’ duration without an identifiable cause in &#173;children younger than 16&#160;years. &#173;There are several subtypes of JIA, which are listed in <span class="xref-table">&#173;Table&#160;24-2</span>.</p>
			<p class="body-text">Overall, the prevalence of uveitis in JIA varies from 2% to 34%. The subtypes of JIA that are particularly associated with uveitis are pauciarticular (oligoarthritis), polyarticular, psoriatic arthritis, and enthesitis-&#173;related arthritis. Uveitis almost never occurs in &#173;children with systemic arthritis and is very rare in &#173;those with rheumatoid &#173;factor–positive polyarticular subtype. In contrast to most forms of anterior uveitis, the uveitis associated with pauciarticular JIA and polyarticular JIA is initially asymptomatic. It has been described as “white iritis” &#173;because of the absence of a red eye. Screening for uveitis among &#173;children with JIA is therefore of &#173;great importance.</p>
			<p class="body-text"><span class="italic">Pauciarticular</span> is the most frequent type of JIA in &#173;children in North Amer&#173;i&#173;ca and Eu&#173;rope. By definition, pauciarticular JIA affects 4 or fewer joints during the first 6 months of the disease. It occurs predominantly in young girls. Anterior uveitis is most likely to occur with this type of arthritis, developing in 10%–30% of patients. Laboratory markers include a high prevalence of antinuclear antibodies (ANA). Rheumatoid factor is almost always absent.</p>
			<p class="body-text">&#173;Children with <span class="italic">polyarticular</span> JIA show involvement of more than 4 inflamed joints during the first 6 months of the disease. This disease is more common in girls, and the mean age at onset is higher compared with pauciarticular JIA. Uveitis occurs in approximately 10% of &#173;these &#173;children. Affected patients may have a positive ANA test result, which is associated with an increased risk of uveitis. &#173;Human leukocyte antigen (HLA) associations have not been consistently documented.</p>
			<p class="body-text">The pathogenesis of the anterior uveitis associated with JIA is unknown, but it is likely to have an immunologic basis. The risk for development of uveitis is highest during the first 4&#160;years &#173;after diagnosis of JIA. Among patients with JIA, 90% of uveitis cases develop within 7&#160;years of onset of arthritis. Occasionally, uveitis is diagnosed before or at the onset of joint symptoms; in &#173;these cases, unfortunately, the prognosis is often poorer &#173;because the initially asymptomatic nature of the ocular inflammation often delays diagnosis and thus treatment. A shorter interval between the onset of arthritis and uveitis is also associated with a more aggressive course.</p>
			<p class="body-text">JIA-&#173;associated uveitis is usually bilateral and nongranulomatous with fine to medium-&#173;sized keratic precipitates, but a minority of &#173;children, especially African Americans, may have granulomatous precipitates. Chronic inflammation may produce band keratopathy (<span class="xref-figure">Fig 24-1</span>), posterior synechiae, ciliary membrane formation, hypotony, cataract, glaucoma, and phthisis. Vitritis and macular edema occur infrequently.</p>
			<p class="h3">Screening for uveitis</p>
			<p class="body-text--no-indent-">Recognition of the importance of screening for uveitis in &#173;children with JIA has resulted in an improved prognosis for this disorder. However, visual impairment has been reported in up to 40% of &#173;children with JIA-&#173;associated uveitis, and blindness may occur in as many as 10% of affected eyes. Screening guidelines continue to undergo revision but are based on 4 &#173;factors that are associated with an increased risk of uveitis:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-3">category of arthritis</li>
				<li class="bullet-list-mid ParaOverride-3">age at onset of arthritis</li>
				<li class="bullet-list-mid ParaOverride-3">presence of ANA positivity</li>
				<li class="bullet-list-last ParaOverride-3">duration of the disease</li>
			</ul>
			<p class="body-text"><span class="xref-table">&#173;Table&#160;24-3</span> outlines the eye examination schedule for pauciarticular and polyarticular JIA, as recommended by the American Acad&#173;emy of Pediatrics. &#173;After 4&#160;years, the eye examinations become less frequent. Although female sex is associated with a higher incidence of uveitis, this &#173;factor is not incorporated in the guidelines. Initial ophthalmologic examination should occur within 6 weeks of diagnosis.</p>
			<p class="h2">Juvenile Spondyloarthropathies</p>
			<p class="body-text--no-indent-">Juvenile spondyloarthropathies are a group of HLA-&#173;B27–&#173;associated disorders and are associated with uveitis in 25% of affected individuals. Boys are more commonly affected than girls, and the disease onset is usually in early adolescence. &#173;There are differentiated and undifferentiated forms. Differentiated types include enthesitis-&#173;related arthritis, juvenile ankylosing spondylitis, juvenile psoriatic arthritis, reactive arthritis, and the arthritis associated with inflammatory bowel disease (enteropathic) (<span class="xref-table">&#173;Table&#160;24-4</span>). A unifying feature of the differentiated forms is enthesitis, an inflammation of the sites where the ligaments, tendons, and joint capsules attach to bone. Enthesitis most commonly affects the insertions of the patellar ligament at the inferior patella, plantar fascia at the calcaneus, and the Achilles tendon. Asymmetric lower-&#173;extremity oligoarthritis with involvement of the hips and midfoot is highly suggestive of the disease.</p>
			<p class="body-text">The anterior uveitis associated with juvenile spondyloarthropathies usually has an acute onset with photophobia, pain, and a red eye.</p>
			<p class="reference--journal--single">Gmuca S, Weiss PF. Juvenile spondyloarthritis. <span class="italic">Curr Opin Rheumatol</span>. 2015;27(4):364–372.</p>
			<p class="h2">Tubulointerstitial Nephritis and Uveitis Syndrome</p>
			<p class="body-text--no-indent-">Tubulointerstitial nephritis and uveitis (TINU) syndrome is kidney disease associated with chronic or recurrent anterior uveitis in adolescents. The median age at onset is 15&#160;years. The renal disease is characterized by low-&#173;grade fever, fatigue, pallor, and weight loss. Elevated levels of β<span class="subscript CharOverride-1">2</span>-&#173;microglobulin are usually pres&#173;ent in the urine. The uveitis is usually bilateral and may occur before, si&#173;mul&#173;ta&#173;neously with, or &#173;after the renal disease. The prognosis is generally good, but long-&#173;term follow-up is required &#173;because the inflammation may recur.</p>
			<p class="h2">Kawasaki Disease</p>
			<p class="body-text--no-indent-">Kawasaki disease, also known as <span class="italic">mucocutaneous lymph node syndrome,</span> is a primary vasculitis mediated by immunoglobulin (Ig) A affecting &#173;children younger than 5&#160;years. Abnormalities include fever, conjunctival injection, mucous membrane changes, extremity changes involving the skin, rash, and cervical lymphadenopathy. The most significant complication of Kawasaki disease is coronary artery aneurysm, which occurs in 15%–25% of untreated &#173;children. Treatment with aspirin and intravenous IgG reduces the incidence of coronary artery aneurysm formation. &#173;After conjunctivitis, a generally self-&#173;limited anterior uveitis during the acute phase of the illness is the second most common ocular finding, occurring in approximately 10% of cases.</p>
			<p class="h2">Other &#173;Causes of Anterior Uveitis</p>
			<p class="body-text--no-indent-">Many cases of anterior uveitis are idiopathic or are caused by trauma. Other &#173;causes include a variety of infectious and noninfectious diseases (see <span class="xref-table">&#173;Table&#160;24-1</span>).</p>
			</div>
			<p class="h1">Intermediate Uveitis</p>
			<div id="Chapt24_Top4">
			<p class="body-text--no-indent-">The term <span class="italic">intermediate uveitis</span> is an anatomically based description of the primary site of the ocular inflammation. The inflammation is localized to the vitreous base overlying the ciliary body, pars plana, and peripheral ret&#173;ina, as well as the anterior vitreous (<span class="xref-figure">Fig 24-2</span>). Intermediate uveitis accounts for 12%–28% of uveitis cases in the pediatric age group. In &#173;children, it may occur with vari&#173;ous conditions, including sarcoidosis, syphilis, Lyme disease, multiple sclerosis, and tuberculosis. Idiopathic disease, known as <span class="italic">pars planitis,</span> accounts for 85%–90% of cases.</p>
			</div>
			<p class="h1">Posterior Uveitis</p>
			<div id="Chapt24_Top5">
			<p class="body-text--no-indent-"><span class="italic">Posterior uveitis</span> is defined as intraocular inflammation primarily involving the choroid; often, &#173;there is also ret&#173;i&#173;nal involvement.</p>
			<p class="h2">Toxoplasmosis</p>
			<p class="body-text--no-indent-">Toxoplasmosis is the most common cause of posterior uveitis in &#173;children. It is discussed in Chapter&#160;28.</p>
			<p class="h2">Toxocariasis</p>
			<p class="body-text--no-indent-">Ocular toxocariasis is caused by the nematode larvae of a common intestinal parasite of dogs <span class="italic">(Toxocara canis)</span> or cats <span class="italic">(Toxocara cati).</span> This disease, contracted through ingestion of ascarid ova in soil contaminated by dog or cat feces, primarily affects &#173;children. <span class="italic">Visceral </span><span class="italic">larva migrans (VLM)</span> is an acute systemic infection produced by &#173;these organisms; it commonly occurs at approximately age 2&#160;years. If symptomatic, it is associated with fever, cough, rashes, malaise, and anorexia. Laboratory testing reveals eosinophilia. VLM and ocular toxocariasis, for unknown reasons, seldom occur in the same patient.</p>
			<p class="body-text">Ocular toxocariasis is usually unilateral and is not associated with systemic illness or an elevated eosinophil count. The average age at onset is 11.5&#160;years. The 3 major ret&#173;i&#173;nal forms of the disease include posterior pole granuloma, peripheral granuloma with macular traction (<span class="xref-figure">Fig 24-3</span>), and endophthalmitis. &#173;There is often &#173;little external evidence of inflammation. Patients may pres&#173;ent with leukocoria, strabismus, or decreased vision. &#173;These are also common presenting signs and symptoms of retinoblastoma, which must be differentiated from ocular toxocariasis. &#173;Because elevated <span class="italic">Toxocara</span> titers may be found in a significant percentage of &#173;children, a positive result on tests such as the enzyme-&#173;linked immunosorbent assay does not rule out other possibilities, including retinoblastoma.</p>
			<p class="body-text">Treatment includes observation of peripheral lesions, periocular or systemic ste&#173;roids for posterior lesions and endophthalmitis, or surgical intervention to address ret&#173;i&#173;nal traction, cataract, glaucoma, or cyclitic membranes. Systemic anthelmintics are not useful in treating ocular toxocariasis &#173;because the organism may already be dead or its death can produce significant inflammation.</p>
			<p class="reference--journal--single">Woodhall D, Starr MC, Montgomery SP, et&#160;al. Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic subspecialists. <span class="italic">Ophthalmology.</span> 2012;119(6):1211–1217.</p>
			<p class="h2">Other &#173;Causes of Posterior Uveitis</p>
			<p class="body-text--no-indent-">Other &#173;causes of posterior uveitis are listed in <span class="xref-table">&#173;Table&#160;24-1</span>.</p>
			</div>
			<p class="h1">Panuveitis</p>
			<div id="Chapt24_Top6">
			<p class="body-text--no-indent-">In panuveitis, inflammation is diffuse without a predominant site. Inflammation is observed in the anterior chamber, vitreous, and choroid.</p>
			<p class="h2">Sarcoidosis</p>
			<p class="body-text--no-indent-">Sarcoidosis may pres&#173;ent in 2 distinct forms in &#173;children. In young patients (<span class="symbol">&lt;</span>5&#160;years), lung disease is rare, and sarcoidosis is more often characterized by the triad of uveitis, granulomatous arthritis, and rash. Early-&#173;onset sarcoidosis is considered a <span class="italic">pediatric granulomatous arthritis</span> and is phenotypically and genet&#173;ically similar to familial juvenile systemic granulomatosis (discussed in the following section). Older &#173;children (8–15&#160;years) with sarcoidosis have the pulmonary abnormalities and lymph node findings more commonly associated with the adult form of the disease and are also at risk for uveitis. Although anterior uveitis (<span class="xref-figure">Fig 24-4</span>) is the most common manifestation of ocular sarcoidosis in &#173;children, this disease can produce a panuveitis.</p>
			<p class="body-text">Diagnosis and treatment in &#173;children is similar to that in adults (see BCSC Section&#160;9, <span class="italic">Intraocular Inflammation and Uveitis</span>). However, serum angiotensin-&#173;converting enzyme levels, which may be abnormally elevated in patients with sarcoidosis, are normally higher in healthy &#173;children than in adults and thus can be misleading in diagnosis of this disease.</p>
			<p class="h2 ParaOverride-4">Familial Juvenile Systemic Granulomatosis</p>
			<p class="body-text--no-indent-">Familial juvenile systemic granulomatosis <span class="italic">(Blau syndrome)</span> is an autosomal dominant disease that may be identical to early-&#173;onset sarcoidosis; both are classified as <span class="italic">pediatric granu</span><span class="italic">lomatous arthritides.</span> In both diseases, &#173;there are mutations in the nucleotide binding oligomerization domain containing 2 gene <span class="italic">(NOD2)</span> on chromosome 16; however, in Blau syndrome, other &#173;family members are affected. Both diseases pres&#173;ent with granulomatous arthritis, uveitis, and rash during childhood, but pulmonary involvement and lymphadenopathy are absent in Blau syndrome. Chronic panuveitis associated with multifocal choroiditis is the most common ocular pre&#173;sen&#173;ta&#173;tion; in some cases, the uveitis may be limited to the anterior segment and the disease misdiagnosed as JIA. Ocular complications, including cataract, glaucoma, band keratopathy, and vision loss, are common.</p>
			<p class="h2 ParaOverride-4">Vogt-&#173;Koyanagi-&#173;Harada Syndrome</p>
			<p class="body-text--no-indent-">Vogt-&#173;Koyanagi-&#173;Harada syndrome is a chronic, progressive bilateral panuveitis that is associated with exudative ret&#173;i&#173;nal detachments and may be accompanied by meningeal irritation, auditory disturbances, and skin changes. It is rare in &#173;children, but in &#173;those affected, the rate of ocular complications such as cataract and glaucoma is higher and the visual prognosis poorer compared with that for adults. For further discussion, see BCSC Section&#160;9, <span class="italic">Intraocular Inflammation and Uveitis.</span></p>
			<p class="h2 ParaOverride-4">Other &#173;Causes of Panuveitis</p>
			<p class="body-text--no-indent-">Other &#173;causes of panuveitis are listed in <span class="xref-table">&#173;Table&#160;24-1</span>.</p>
			</div>
			<p class="h1 ParaOverride-5">Masquerade Syndromes</p>
			<div id="Chapt24_Top7">
			<p class="body-text--no-indent-">Vari&#173;ous conditions can simulate pediatric uveitis. <span class="xref-table">&#173;Table&#160;24-5</span> lists &#173;these masquerade syndromes and their diagnostic features.</p>
			</div>
			<p class="h1 ParaOverride-5">Evaluation of Pediatric Uveitis</p>
			<div id="Chapt24_Top8">
			<p class="body-text--no-indent-">Establishing the correct diagnosis is impor&#173;tant in managing a pediatric patient with uveitis, but some ophthalmologists defer the workup of isolated anterior uveitis &#173;unless it is recurrent or unresponsive to initial therapy. Accurate diagnosis requires a detailed history, thorough ophthalmic examination, and selected laboratory tests. An examination &#173;under anesthesia may be necessary if the child is not cooperative enough for an office evaluation. Laboratory investigations are chosen based on the suspected diagnoses (<span class="xref-table">&#173;Table&#160;24-6</span>; see also <span class="xref-table">&#173;Table&#160;24-5</span>).</p>
			</div>
			<p class="h1">Treatment of Pediatric Uveitis</p>
			<div id="Chapt24_Top9">
			<p class="body-text--no-indent-">The goals of treatment of uveitis in &#173;children are to eliminate the inflammation of the eye before ocular complications occur and to monitor for ocular and systemic adverse effects of the treatment. It is impor&#173;tant to note that although the presence of cells in the anterior chamber indicates active inflammation, flare (protein) may persist long &#173;after the inflammation has been successfully treated.</p>
			<p class="body-text">Infectious diseases and malignancies producing uveitis should be identified and treated appropriately. Treatment of noninfectious uveitis is discussed in the following sections.</p>
			<p class="h2">Management of Inflammation</p>
			<p class="body-text--no-indent-">Anterior segment inflammation is initially treated with topical corticosteroid and mydriatic/cycloplegic agents. &#173;Because topical corticosteroids do not penetrate well into the vitreous or posterior segment, sub-&#173;Tenon injections of a corticosteroid may be useful in the treatment of intermediate or posterior uveitis. Short courses of oral corticosteroids may be used, but long-&#173;term use is usually avoided &#173;because of the potential for significant ocular and systemic adverse effects. Corticosteroid intravitreal implants containing &#173;either fluocinolone aceto&#173;nide or dexamethasone have been used successfully to treat posterior uveitis in &#173;children.</p>
			<p class="body-text">Glaucoma and cataract formation are the most serious ocular complications of any corticosteroid therapy. In general, more potent topical corticosteroids are more likely to increase intraocular pressure. Periocular injections of corticosteroids can elevate intraocular pressure for weeks to months &#173;after injection. Cataracts and glaucoma are reported adverse effects of intravitreal ste&#173;roid implants. Risks of long-&#173;term systemic corticosteroid use in &#173;children include growth retardation, osteoporosis and bone fractures, cushingoid appearance, diabetes mellitus, peptic ulcers, myopathy, hypertension, altered &#173;mental status, idiopathic intracranial hypertension, and increased risk of infection. Patients may also require increased doses of corticosteroids during times of stress to avoid an addisonian crisis.</p>
			<p class="body-text">Systemic immunosuppressive therapy is beneficial in treating both uveitis and arthritis. It can sometimes reduce or eliminate the need for ste&#173;roids. The therapy should be undertaken in cooperation with a pediatric specialist familiar with the use of immunosuppressive and immunomodulatory medi&#173;cations. In patients with JIA, immunosuppressive drugs reduce the risk of vision loss from uveitis.</p>
			<p class="body-text">Methotrexate is the most common antimetabolite used to treat arthritis and uveitis in &#173;children. Less commonly used antimetabolites include azathioprine and mycophenolate mofetil. &#173;These agents inhibit nucleic acid synthesis by a variety of mechanisms. Gastrointestinal disturbance is the most common adverse effect of oral methotrexate and can be alleviated by switching to subcutaneous injections. Oral folic acid supplementation is often recommended for patients using methotrexate. Hepatic toxicity, interstitial pneumonitis, and cytopenia are rare but serious adverse effects of methotrexate use.</p>
			<p class="body-text">Biologic drugs for the treatment of uveitis are used with increasing frequency to suppress the immune system in &#173;children. The 2 classes of biologic medi&#173;cations are tumor necrosis &#173;factor α (TNF-α) inhibitors and cell-&#173;specific antibodies. The TNF-&#173;α inhibitors most commonly used to treat uveitis are infliximab and adalimumab, which are monoclonal IgG antibodies against TNF-&#173;α. Commonly used cell-&#173;specific antibodies include abatacept (antibody to CD80 and CD86) and rituximab (antibody to interleukin-2). Etanercept should be avoided &#173;because new-&#173;onset inflammatory eye disease (uveitis, scleritis, optic neuritis) has been associated with its use, caused by poor drug efficacy and/or adverse effect of the drug. In general, TNF-&#173;α inhibitors are used before cell-&#173;specific antibodies. TNF-&#173;α inhibitors should not be used during periods of active infection. All &#173;these biologic drugs used to treat uveitis require intravenous infusion, except for adalimumab, which can be given subcutaneously. &#173;There is concern that &#173;children and adolescents treated with TNF-&#173;α blockers may be at increased risk for malignancies; however, a recent study showed that &#173;children with JIA are at increased risk for malignancies unrelated to the use of biologic drugs.</p>
			<p class="reference--journal--first">Beukelman T, Haynes K, Curtis JR, et&#160;al; Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. <span class="italic">Arthritis Rheum.</span> 2012;64(4):1263–1271.</p>
			<p class="reference--journal--mid">Gregory AC II, Kempen JH, Daniel E, et&#160;al; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group. Risk &#173;factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. <span class="italic">Ophthalmology.</span> 2013;120(1):186–192.</p>
			<p class="reference--journal--mid"><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Klotsche%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25926155">Klotsche J</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Niewerth%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25926155">Niewerth M</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Haas%20JP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25926155">Haas JP</a>. Long-&#173;term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). <a href="https://www.ncbi.nlm.nih.gov/pubmed/25926155"><span class="italic">Ann Rheum Dis.</span></a> 2016;75(5):855–861.</p>
			<p class="reference--journal--mid">Reiff A, Kadayifcilar S, <span class="accent">Ö</span>zen S. Rheumatic inflammatory eye diseases of childhood. <span class="italic">Rheum Dis Clin North Am.</span> 2013;39(4):801–832.</p>
			<p class="h2 ParaOverride-6">Surgical Treatment of Complications of Uveitis</p>
			<p class="body-text--no-indent-">Complications of uveitis include band keratopathy, cataract, and glaucoma. Band keratopathy can be treated by removal of corneal epithelium, followed by calcium chelation with ethylenediaminetetraacetic acid (EDTA). Treatment may have to be repeated. Phototherapeutic keratectomy has also been used to treat band keratopathy.</p>
			<p class="body-text">Cataract surgery for patients with uveitis can be complicated by hypotony, glaucoma, synechiae formation, cystoid macular edema, and ret&#173;i&#173;nal detachment. In patients with JIA, combined lensectomy and vitrectomy seems to produce better results than cataract extraction alone. Uveitis must be aggressively treated so that it is &#173;under control both before and &#173;after surgery. Intraocular lens implantation is usually not considered in &#173;children with uveitis &#173;until &#173;after a prolonged period of quiescence.</p>
			<p class="body-text">Glaucoma surgery may become necessary in &#173;children with uveitis. Many techniques have been used, and long-&#173;term success rates vary. Standard trabeculectomy is associated with a high rate of failure due to scarring. Goniotomy or trabeculotomy is effective in many &#173;children and can be the initial surgery if the anterior chamber &#173;angle is vis&#173;i&#173;ble. Tube shunts can be used when goniotomy fails or if the &#173;angle is closed.</p>
			<p class="reference--journal--single">Bohnsack BL, Freedman SF. Surgical outcomes in childhood uveitic glaucoma. <span class="italic">Am J Ophthalmol.</span> 2013;155(1):134–142.</p>
		</div>
		</div>
		<div id="_idContainer001" class="Basic-Text-Frame">
			<table id="table001" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="3">
							<p class="table-title"><span class="table-number">&#173;Table&#160;24-1</span> Differential Diagnosis of Uveitis in &#173;Children</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-1" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-1">
							<p class="table-head"><span class="bold-table">Anterior uveitis</span></p>
						</td>
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-1" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style _5-BCSC-table-body" />
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-body ParaOverride-3">Juvenile idiopathic arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Trauma</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Sarcoidosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Tuberculosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Syphilis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Lyme disease</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Herpes virus</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Kawasaki disease</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Tubulointerstitial nephritis and uveitis syndrome</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Beh<span class="table-accent">ç</span>et disease</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Inflammatory bowel disease</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Granulomatosis with polyangiitis (Wegener granulomatosis)</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Nonspecific orbital inflammation (orbital pseudotumor)</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Idiopathic anterior uveitis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-3" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-4">
							<p class="table-head"><span class="bold-table">Intermediate uveitis</span></p>
						</td>
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-3" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-5" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-5">
							<p class="table-body ParaOverride-3">Sarcoidosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-5" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Tuberculosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Syphilis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Lyme disease</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Multiple sclerosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Idiopathic intermediate uveitis (pars planitis)</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-4" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-4">
							<p class="table-head"><span class="bold-table">Posterior uveitis and panuveitis</span></p>
						</td>
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-4" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-5" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-6">
							<p class="table-body ParaOverride-3">Toxoplasmosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-5" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Toxocariasis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Sarcoidosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Tuberculosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Syphilis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Lyme disease</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Herpes virus</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Rubella or measles</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Sympathetic ophthalmia</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3"><span class="table-italic">Bartonella henselae</span> infection (cat-&#173;scratch disease)</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3"><span class="table-italic">Candida albicans</span> infection</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Familial juvenile systemic granulomatosis (Blau syndrome)</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Diffuse unilateral subacute neuroretinitis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Vogt-&#173;Koyanagi-&#173;Harada syndrome</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-3">Beh<span class="table-accent">ç</span>et disease</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7">
							<p class="table-body ParaOverride-3">Idiopathic posterior uveitis or panuveitis</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer002" class="Basic-Text-Frame">
			<table id="table002" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-6" />
					<col class="_idGenTableRowColumn-7" />
					<col class="_idGenTableRowColumn-6" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="3">
							<p class="table-title"><span class="table-number">&#173;Table&#160;24-2</span> Subtypes of Juvenile Idiopathic Arthritis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-8" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-8">
							<p class="table-body ParaOverride-7">&#9;I. &#9;Systemic arthritis</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-8" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">&#9;II.&#9; Pauciarticular arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">&#9;III.&#9;Polyarticular arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">&#9;IV.&#9;Spondyloarthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-8">A.&#9;Enthesitis-&#173;related arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-8">B.&#9;Juvenile psoriatic arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-8">C.&#9;Juvenile ankylosing spondylitis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-8">D.&#9;Enteropathic arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-8">E.&#9;Reactive arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-8">F.&#9;Undifferentiated spondyloarthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7">
							<p class="table-body ParaOverride-7">&#9;V.&#9;Undifferentiated arthritis</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer006">
				<div id="_idContainer004" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 24-1</span> Slit-lamp photograph from a patient with uveitis associated with juvenile idiopathic arthritis (JIA). As is typical in pauciarticular or polyarticular JIA, the conjunctiva is “white.” Band keratopathy is present. <span class="figure-source-note">(Courtesy of Amy Hutchinson, MD.)</span></p>
				</div>
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="OPERATOR-BCSC1819_S06_C24_p001-014_1P-web-resources/image/AAX-3539.jpg" alt="" />
				</div>
			</div>
		</div>
		<div id="_idContainer007" class="Basic-Text-Frame">
			<table id="table003" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-9" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-9" />
					<col class="_idGenTableRowColumn-14" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="9">
							<p class="table-title"><span class="table-number">&#173;Table&#160;24-3</span> Frequency of Eye Examination in Patients With Pauciarticular <br />or Polyarticular JIA</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-16">
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-9" />
						<td class="No-Table-Style _3-BCSC-table-column-head" rowspan="2">
							<p class="table-column-head ParaOverride-9"><span class="bold-table">Age at Onset of JIA, y</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-10" />
						<td class="No-Table-Style _3-BCSC-table-column-head" rowspan="2">
							<p class="table-column-head ParaOverride-9"><span class="bold-table">Duration of Disease, y</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-9" />
						<td class="No-Table-Style _3-BCSC-table-column-head" colspan="3">
							<p class="table-column-head ParaOverride-9"><span class="bold-table">Eye Examination Frequency <br />(mo) for ANA-&#173;Positive, <br />ANA-&#173;Negative Patients</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-11 _idGenCellOverride-1" />
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-12 _idGenCellOverride-1" />
						<td class="No-Table-Style _3-BCSC-table-column-head CellOverride-11 _idGenCellOverride-1" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head ParaOverride-9"><span class="bold-table">ANA</span><span class="bold-table_symbol">+</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head ParaOverride-9"><span class="bold-table">ANA–</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13">
							<p class="table-body ParaOverride-9"><span class="symbol">≤</span>6</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-14" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13">
							<p class="table-body ParaOverride-7"><span class="symbol">≤</span>4</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13">
							<p class="table-body ParaOverride-7">3</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13">
							<p class="table-body ParaOverride-7">6</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-9"><span class="symbol">≤</span>6</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-15" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7"><span class="symbol">&gt;</span>4 to <span class="symbol">≤</span>7</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">6</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">12</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-9"><span class="symbol">≤</span>6</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-15" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7"><span class="symbol">&gt;</span>7</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">12</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">12</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-9"><span class="symbol">&gt;</span>6</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-15" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7"><span class="symbol">≤</span>4</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">6</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-body ParaOverride-7">12</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7">
							<p class="table-body ParaOverride-9"><span class="symbol">&gt;</span>6</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-15" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7">
							<p class="table-body ParaOverride-7"><span class="symbol">&gt;</span>4</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7">
							<p class="table-body ParaOverride-7">12</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7">
							<p class="table-body ParaOverride-7">12</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-7" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-17">
						<td class="No-Table-Style _8-BCSC-table-note" colspan="9">
							<p class="table-footnote">ANA <span class="symbol">=</span> antinuclear antibody; JIA <span class="symbol">=</span> juvenile idiopathic arthritis.</p>
							<p class="table-footnote ParaOverride-10">Frequencies are for the first 4&#160;years &#173;after diagnosis.</p>
							<p class="table-footnote ParaOverride-11">Information from Cassidy J, Kivlin J, Lindsley C, Nocton J; Section on Rheumatology; Section on Ophthalmology. Ophthalmologic examinations in &#173;children with juvenile rheumatoid arthritis. <span class="table-italic">Pediatrics.</span> 2006;117(5):1844.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer008" class="Basic-Text-Frame">
			<table id="table004" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-18" />
					<col class="_idGenTableRowColumn-19" />
					<col class="_idGenTableRowColumn-20" />
					<col class="_idGenTableRowColumn-19" />
					<col class="_idGenTableRowColumn-21" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="5">
							<p class="table-title"><span class="table-number">&#173;Table&#160;24-4</span> Types of Juvenile Spondyloarthropathies</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head"><span class="bold-table">Type</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head"><span class="bold-table">Additional Systemic Manifestations</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head"><span class="bold-table">Uveitis Prevalence and Characteristics</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-22">
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13">
							<p class="table-body">Enthesitis-&#173;related arthritis</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13">
							<p class="table-body ParaOverride-12">None</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-13">
							<p class="table-body">Occurs in 20% of affected &#173;children</p>
							<p class="table-body">Acute, symptomatic</p>
							<p class="table-body">Unilateral, but both eyes may <br />be affected at dif&#173;fer&#173;ent <br />times</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-23">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Juvenile psoriatic arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body ParaOverride-12">Nail changes (pitting or onycholysis), dactylitis, psoriasis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Occurs in 10% of affected &#173;children</p>
							<p class="table-body">Insidious and chronic anterior uveitis</p>
							<p class="table-body ParaOverride-12">Usually bilateral</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-24">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Juvenile ankylosing spondylitis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Involves the spine</p>
							<p class="table-body">Sacroiliitis, which may be subclinical</p>
							<p class="table-body ParaOverride-12">Cardiac disease rare in &#173;children</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Occurs in 20%–30% of &#173;those affected</p>
							<p class="table-body">Acute, symptomatic</p>
							<p class="table-body ParaOverride-12">Unilateral, but both eyes may <br />be affected at dif&#173;fer&#173;ent <br />times</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Enteropathic arthritis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body ParaOverride-12">Crohn disease, ulcerative colitis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body ParaOverride-12">Occurs in 5% of &#173;those affected</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-26">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16">
							<p class="table-body">Reactive arthritis</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16">
							<p class="table-body">Follows an infection not involving the joints</p>
							<p class="table-body ParaOverride-12">Urethritis</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16">
							<p class="table-body">Occurs in 12% of &#173;those affected</p>
							<p class="table-body">Acute, symptomatic</p>
							<p class="table-body">Unilateral and recurrent anterior uveitis</p>
							<p class="table-body ParaOverride-12">Conjunctivitis may also be pres&#173;ent</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer011">
				<div id="_idContainer009" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 24-2</span> Intermediate uveitis with inferior snowbank formation (inflammatory exudative accumulation on the inferior pars plana [“snow bank”]), right eye.</p>
				</div>
				<div id="_idContainer010" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="OPERATOR-BCSC1819_S06_C24_p001-014_1P-web-resources/image/AAX-2329.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer014">
				<div id="_idContainer012" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="OPERATOR-BCSC1819_S06_C24_p001-014_1P-web-resources/image/KIN00936.png" alt="" />
				</div>
				<div id="_idContainer013" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 24-3</span> Toxocariasis. <span class="figure-caption-bold">A,</span> Distortion of posterior pole vessels, right eye. <span class="figure-caption-bold">B,</span> Fundus photograph showing macular granuloma. <span class="figure-caption-bold">C,</span> Fundus photograph of peripheral granuloma.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer017">
				<div id="_idContainer015" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 24-4</span> Keratic precipitates in sarcoidosis. <span class="figure-source-note">(Courtesy of Ken K. Nischal, MD.)</span></p>
				</div>
				<div id="_idContainer016" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-1" src="OPERATOR-BCSC1819_S06_C24_p001-014_1P-web-resources/image/AAX-6707.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer019" class="Basic-Text-Frame">
			<table id="table005" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-27" />
					<col class="_idGenTableRowColumn-28" />
					<col class="_idGenTableRowColumn-29" />
					<col class="_idGenTableRowColumn-28" />
					<col class="_idGenTableRowColumn-30" />
					<col class="_idGenTableRowColumn-28" />
					<col class="_idGenTableRowColumn-31" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="7">
							<p class="table-title"><span class="table-number">&#173;Table&#160;24-5</span> Uveitis Masquerade Syndromes in &#173;Children</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head"><span class="bold-table">Disease or Condition</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head"><span class="bold-table">Age, y</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head"><span class="bold-table">Signs of Inflammation</span></p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head"><span class="bold-table">Examination/Diagnostic Studies</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-32">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8">
							<p class="table-head"><span class="bold-table">Anterior segment</span></p>
						</td>
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8" />
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8" />
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-4">
							<p class="table-body">Retinoblastoma</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-4" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-4">
							<p class="table-body"><span class="symbol">&lt;</span>15</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-4" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-4">
							<p class="table-body">Flare, cells, pseudohypopyon</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-4" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-4">
							<p class="table-body">Ultrasonography, MRI</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Leukemia</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body"><span class="symbol">&lt;</span>15</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Flare, cells, hypopyon, heterochromia, hyphema</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Bone marrow biopsy, peripheral blood smear</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-4">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Intraocular foreign body</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Any age</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Flare, cells</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">X-&#173;ray, CT, ultrasonography</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Malignant melanoma</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Any age</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Flare, cells</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Fluorescein angiography, ultrasonography, OCT</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Juvenile xanthogranuloma</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body"><span class="symbol">&lt;</span>15</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Flare, cells, hyphema</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Examination of skin, iris biopsy</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Peripheral ret&#173;i&#173;nal detachment</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Any age</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Flare, cells</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Ophthalmoscopy</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-32">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8 _idGenCellOverride-2" colspan="7">
							<p class="table-head"><span class="bold-table">Posterior segment</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-33">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-17">
							<p class="table-body">Retinitis pigmentosa</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-17" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-17">
							<p class="table-body">Any age</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-17" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-17">
							<p class="table-body">Cells in vitreous, waxy disc pallor, bone-&#173;spicule pigmentary changes in midperiphery</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-17" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-17">
							<p class="table-body">ERG, visual fields</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-34">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Systemic lymphoma</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body"><span class="symbol">≥</span>15</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Ret&#173;i&#173;nal hemorrhage or exudates, vitreous cells</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Node biopsy, bone marrow biopsy, physical examination</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Retinoblastoma</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body"><span class="symbol">&lt;</span>15</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Vitreous cells, ret&#173;i&#173;nal exudates</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Ultrasonography, MRI</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-25">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Malignant melanoma</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body"><span class="symbol">≥</span>15</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Vitreous cells</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-4">
							<p class="table-body">Fluorescein angiography, ultrasonography, OCT</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-35">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16">
							<p class="table-body">Multiple sclerosis</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16">
							<p class="table-body"><span class="symbol">≥</span>15</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16">
							<p class="table-body">Periphlebitis, pars planitis</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-16">
							<p class="table-body">Neurologic examination</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-36">
						<td class="No-Table-Style _8-BCSC-table-note" colspan="7">
							<p class="table-footnote ParaOverride-7">CT <span class="symbol">=</span> computed tomography; ERG <span class="symbol">=</span> electroretinogram; MRI <span class="symbol">=</span> magnetic resonance imaging; OCT <span class="symbol">=</span> optical coherence tomography.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer020" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer021" class="Basic-Text-Frame">
			<table id="table006" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-37" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _1-BCSC-table-title">
							<p class="table-title"><span class="table-number">&#173;Table&#160;24-6</span> Laboratory Tests and Imaging for Vari&#173;ous Types of Uveitis</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-32">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8">
							<p class="table-head"><span class="bold-table">Anterior uveitis</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Antinuclear antibody (JIA)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">ACE, lysozyme (sarcoidosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Chest x-&#173;ray (sarcoidosis, tuberculosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Tuberculin skin test, interferon-&#173;<span class="xref-table CharOverride-2">γ</span> release assay (tuberculosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">FTA-&#173;ABS (syphilis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Lyme serology (Lyme disease)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Complete blood count (leukemia)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">HLA-&#173;B27 and sacro&#173;iliac joint films (enthesitis-&#173;related arthritis, ankylosing spondylitis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Gastrointestinal series (if ulcerative colitis or regional enteritis [Crohn disease] is suspected)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-2">
							<p class="table-indent-1">Urinalysis, blood urea nitrogen, serum creatinine, urine <span class="greek">β</span><span class="subscript CharOverride-1">2</span>-&#173;microglobulin (TINU syndrome)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Antineutrophil cytoplasmic antibody (granulomatosis with polyangiitis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-32">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8">
							<p class="table-head"><span class="bold-table">Intermediate uveitis</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">ACE, lysozyme (sarcoidosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Chest x-&#173;ray (sarcoidosis, tuberculosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Tuberculin skin test, interferon-&#173;<span class="xref-table CharOverride-2">γ</span> release assay (tuberculosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">FTA-&#173;ABS (syphilis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Lyme serology (Lyme disease)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-32">
						<td class="No-Table-Style _6-BCSC-table-body-head CellOverride-8">
							<p class="table-head"><span class="bold-table">Posterior uveitis and panuveitis</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Toxoplasmosis PCR, ELISA</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Toxocariasis PCR, ELISA</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">ACE, lysozyme (sarcoidosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Chest x-&#173;ray (sarcoidosis, tuberculosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Tuberculin skin test, interferon-&#173;<span class="xref-table CharOverride-2">γ</span> release assay (tuberculosis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">FTA-&#173;ABS (syphilis)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _5-BCSC-table-body">
							<p class="table-indent-1">Lyme serology (Lyme disease)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-18">
							<p class="table-indent-1">PCR, blood cultures, viral cultures, or antibody levels (if cytomegalovirus, herpes simplex, herpes zoster, rubella, measles, or <span class="table-italic">Bartonella henselae</span> infection is suspected)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-38">
						<td class="No-Table-Style _8-BCSC-table-note">
							<p class="table-footnote ParaOverride-7">ACE <span class="symbol">=</span> angiotensin-&#173;converting enzyme; ELISA <span class="symbol">=</span> enzyme-&#173;linked immunosorbent assay; FTA-&#173;ABS <span class="symbol">=</span> fluo&#173;rescent treponemal antibody absorption; HLA <span class="symbol">=</span> &#173;human leukocyte antigen; JIA <span class="symbol">=</span> juvenile idiopathic arthritis; PCR <span class="symbol">=</span> polymerase chain reaction; TINU <span class="symbol">=</span> tubulointerstitial nephritis and uveitis.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
	</body>
</html>
